I���T’ S C���D
THINK
* PAXLOVID is indicated in patients ≥ 18 years with mild-moderate COVID-19, unless contraindicated. Review for drug-drug interactions. Commence within 5 days of symptom onset. 1 PBS restrictions apply. 2
The
First-line oral COVID-19 antiviral treatment unless contraindicated, as required by PBS criteria 2 – 4
Contraindications can be found using the University of Liverpool Drug Checker or PAXLOVID Product Information. 1, 5
Similar rates of adverse events vs placebo 1, 6 ‡
‡
Incidence of treatment-emergent AEs were similar between PAXLOVID( 22.6 %) and placebo( 23.9 %), and mostly mild or moderate. The most common side effects included dysgeusia, diarrhoea, and vomiting, which were mild or moderate and resolved. 6
With proven efficacy:
86 % reduction in COVID-19-related hospitalisation or death 1 †
†
When taken within 5 days of symptom onset in patients with at least one risk factor for severe COVID-19 illness. Efficacy compared with placebo through Day 28 in the EPIC-HR clinical trial( P < 0.001; secondary endpoint) 1, 6
Dosage and Administration: Recommended dose 300 mg nirmatrelvir and 100 mg ritonavir tablets OR 150 mg nirmatrelvir and 100 mg ritonavir in moderate renal impairment, taken together orally every 12 hours for 5 days. 1
Before prescribing, please review full product information available at pfi. sr / paxlovid-pi.
For more information about the PAXLOVID PBS criteria, scan the QR code
This medicinal product is subject to additional monitoring in Australia. This will allow quick identifi cation of new safety information. Healthcare professionals are asked to report any suspected adverse events at www. tga. gov. au / reporting-problems.
Alternatively, any adverse events which are experienced with PAXLOVID ® can be reported to Pfi zer on 1800 675 229 or by email to AUS. AEReporting @ pfi zer. com
Warning: Nirmatrelvir with ritonavir has signifi cant drug-drug interactions. Prescribers and dispensers should carefully review a patient’ s concomitant medications.
PBS Information: Authority Required( STREAMLINED). Category: GENERAL – General Schedule( Code GE). For verified SARS-CoV-2 infection. Treatment must be initiated within 5 days of symptom onset. Refer to PBS Schedule for full authority information.
Abbreviations: AE: adverse event; PBS: Pharmaceutical Benefi ts Scheme.
References: 1. PAXLOVID ® Product Information. 2. Pharmaceutical Benefi ts Scheme. Nirmatrelvir & Ritonavir. Available at: https:// www. pbs. gov. au / medicine / item / 12996B-13147Y. Accessed 4 March 2024. 3. PAXLOVID ®( nirmatrelvir and ritonavir) Pharmaceutical Benefi ts Scheme Factsheet- Updated December 2024. Available at: https:// www. pbs. gov. au / publication / factsheets / covid- 19-treatments / PBS-Factsheet-paxlovid-nirmatrelvir-and-ritonavir-updated-December-2024. pdf. Accessed 10 December 2024. 4. Lagevrio ®( molnupiravir) Pharmaceutical Benefi ts Scheme Factsheet- Updated December 2024. Available at: https:// www. pbs. gov. au / publication / factsheets / covid-19-treatments / PBS-Factsheet-lagevrio-molnupiravir-updated-December-2024. pdf. Accessed 10 December 2024. 5. COVID-19 Drug Interactions. University of Liverpool, 2024. Available at: https:// www. covid19-druginteractions. org / checker. Accessed 4 March 2024. 6. Hammond J et al. N Eng J Med. 2022; 386:1397 – 1408.
© 2025. All rights reserved. Pfi zer Australia Pty Ltd, Sydney, Australia. www. pfi zer. com. au. Medical Information: 1800 675 229. www. pfi zermedicalinformation. com. au. PP-C1D-AUS-0390. AWF-2620100. 02 / 25.